ReviewPrecision radiation oncology2024
Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs.
Review in Precision radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- DMBX1 expression in colon cancer and its impact on prognosis and the tumor microenvironment.BMC medical genomics · 2026Article
- Bibliometric analysis of immune-related acute kidney injury induced by cancer immunotherapy (2000-2025).Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- LncRNAs: key regulators and molecular mechanisms in lung cancer radiosensitivity.Open medicine (Warsaw, Poland) · 2026Review
- Post-pandemic shifts in pediatric respiratory pathogens and co-infection dynamics in Xi'an and surrounding areas: a large-scale retrospective study from 2021 to 2025.BMC infectious diseases · 2025Article
- Radiotherapy for primary bone tumors: current techniques and integration of artificial intelligence-a review.Frontiers in oncology · 2025Review
- Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs.Precision radiation oncology · 2024Review
- Prediction of Local Recurrence Using Clinical and Radiomic Features in Lung Oligometastases Treated with Stereotactic Body Radiotherapy.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung oligometastases represent an intermediate state of cancer dissemination between localized and widespread metastases. Stereotactic body radiation therapy (SBRT) has emerged as an effective treatment option, with an efficacy comparable to that of surgical resection. This review aimed to provide a comprehensive summary of the latest advancements and controversial issues regarding SBRT for lung oligometastases. It focuses on four crucial perspectives: efficacy of SBRT, optimal patient selection criteria, technological innovations, and synergistic effects of SBRT combined with systemic therapy. Relevant clinical trials investigating SBRT for lung oligometastases have been conducted, with median 1- and 5-year local control rates of 90% and 79%, respectively. The origin of the primary tumor, size and number of lesions, and biomarker profiles were highlighted as pivotal considerations in patient selection. The precise dose delivery was enhanced using robotic SBRT and optimized dose fractionation schemes. Evidence suggests that dose escalation above 100 Gy biologically effective dose may improve tumor control. Combined immunotherapy and SBRT have demonstrated synergistic effects in prolonging progression-free survival and overall survival. This review provides valuable insights into the precise treatment of oligometastatic lung diseases using SBRT. Further multicenter randomized trials are warranted to develop definitive patient selection criteria and optimize the integration with systemic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.